Risk of cancers during interrupted antiretroviral therapy in the SMART study

@article{Silverberg2007RiskOC,
  title={Risk of cancers during interrupted antiretroviral therapy in the SMART study},
  author={Michael J. Silverberg and Jacqueline Neuhaus and Mark Bower and Daniela C Gey and Angelos Hatzakis and Keith Henry and Jose A. Hidalgo and Leonardo Lourtau and James D. Neaton and G. Tambussi and Donald I. Abrams},
  journal={AIDS},
  year={2007},
  volume={21},
  pages={1957–1963}
}
Objective:To compare rates of AIDS-defining and non-AIDS-defining malignancies between patients on a CD4 T-cell-guided antiretroviral therapy (ART) strategy and continuous ART. Design:A randomized clinical trial. Methods:Malignancy rates were compared between the drug conservation arm in which ART was stopped if the CD4 T-cell count exceeded 350 cells/μl and (re)started if it fell to less than 250 cells/μl and the viral suppression arm utilizing continuous ART. Cox models were used to examine… 
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons
TLDR
ART exposure was generally not associated with NADC risk, except for long-term use of protease inhibitor, which might be associated with increased anal cancer risk, and no therapy class-specific effect was found for ADC.
Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy.
  • A. Kesselring, L. Gras, F. Wit
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
TLDR
Cumulative exposure to CD4+ cell counts < 200 cells/mm³ during cART was associated with an increased risk of infection-related non-AIDS-defining malignancies and no significant effect of viremia was seen in either type of cancer.
Incidence of Non-AIDS-Defining Cancer in Antiretroviral Treatment-Naïve Subjects after Antiretroviral Treatment Initiation: An ACTG Longitudinal Linked Randomized Trials Analysis
TLDR
Strategies for maintaining higher CD4 cell counts and successful smoking cessation may reduce the NADC incidence in the HIV-infected population.
Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence
TLDR
Poor CD4+ cell count response was strongly associated with virus-related NADC incidence, suggesting an important role for T-cell mediated immunity in pathogenesis and intensified cancer screening should be considered for patients on ART with low CD4- cell counts.
Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?
TLDR
Successful ART use and improvements in immune function for HIV-infected persons may reduce the risk of certain NADMs, however, a continued high risk in the ART era for certain cancers have been observed, including Hodgkin's lymphoma and anal cancers.
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era
TLDR
Traditional risk factors play a significant role in the increased risk of non-AIDS-defining malignancies for HIV-infected individuals, but do not entirely explain the excess cancer risk.
Non–AIDS-Defining Malignancies in Patients with HIV in the HAART Era
TLDR
The causes underlying the rise in incidence of NADM and the clinical presentation, pathology, and treatment outcomes of the four most commonly encountered NADM in the HAART era are reviewed.
Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier?
TLDR
It remains unclear whether earlier initiation (CD4+ cell count above 350/microL) of antiretroviral therapy may be beneficial in preventing non-AIDS-defining cancer.
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
TLDR
Higher CD4+ counts on antiretroviral therapy are associated with lower rates of non-AIDS diseases and AIDS, and these findings expand the understanding of the implications of HIV-related immunodeficiency.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial
TLDR
Prolonged STI in patients with fully suppressed virus and marked immune reconstitution is generally safe and the main predictor ofCD4 cell decline is the nadir CD4 cell count.
A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
  • P. Cardiello, E. Hassink, D. Cooper
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
WOWO therapy maintained a CD4 cell count of > or =350 cells/microL in almost all patients but was associated with high virological failures rates (possibly resulting from previous dual-NRTI therapy), indicating that this strategy is less useful.
CD4+ count-guided interruption of antiretroviral treatment.
TLDR
Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load.
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.
TLDR
The incidence of NHL among HIV-infected patients has decreased significantly after the introduction of HAART, and the decline was most pronounced for PBL.
HIV-related lung cancer in the era of highly active antiretroviral therapy
TLDR
HIV-related lung cancer occurred more frequently in the post-HAART era, when compared with the HIV-negative population, and the outcome of these patients remains poor despite HAART.
Association of cancer with AIDS-related immunosuppression in adults.
TLDR
Although occurring in overall excess, most non-AIDS-defining cancers do not appear to be influenced by the advancing immunosuppression associated with HIV disease progression.
AIDS across Europe, 1994–98: the EuroSIDA study
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
TLDR
The overall incidence of NADCs was increased in HIV-infected men but not in women and did not differ between P1 and P2, relative to FGP.
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis
TLDR
There is reassuring evidence that people with HIV who are only mildly immune deficient may not be at increased risk of non-AIDS-defining cancers, but larger studies with longer periods of follow-up are needed to confirm this.
...
...